Update on clindamycin in the management of bacterial, fungal and protozoal infections

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2401-2444

  Guay, David ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anaerobic infection; Babesiosis; Clindamycin; Dental infection; Intra abdominal sepsis; Lincosamide; Malaria; Pneumocystosis; Toxoplasmosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ARTESUNATE; AZITHROMYCIN; CEFAZOLIN; CEFODIZIME; CIPROFLOXACIN; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FANSIDAR; FOSMIDOMYCIN; GENTAMICIN; IMIPENEM; LINCOMYCIN; MACROLIDE; METICILLIN; METRONIDAZOLE; PANIPENEM PLUS BETAMIPRON; PENICILLIN G; PENICILLIN V; PLACEBO; QUININE; STREPTOGRAMIN DERIVATIVE; SULTAMICILLIN; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ASPIRATION PNEUMONIA; BABESIA; BABESIOSIS; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; CONVULSION; DIABETIC FOOT; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG WITHDRAWAL; ENDOMETRITIS; EPIGASTRIC DISCOMFORT; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION PREVENTION; INJECTION SITE PAIN; LOADING DRUG DOSE; MALARIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OSTEOMYELITIS; PLASMODIUM FALCIPARUM; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PROTOZOAL INFECTION; PSEUDOMEMBRANOUS COLITIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TOOTH INFECTION; TOXOPLASMA GONDII; UNSPECIFIED SIDE EFFECT; VAGINITIS; VOMITING;

ANIMALS; BACTERIAL INFECTIONS; CLINDAMYCIN; HUMANS; MYCOSES; PROTOZOAN INFECTIONS;

EID: 35548933779     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2401     Document Type: Review

References (243)

1. SPIZEK J, NOVOTNA J, REZANKA T: Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. Adv. Appl. Microbiol. (2004) 56:121-154.
2. SPIZEK J, REZANKA T: Lincomycin, clindamycin and their applications. Appl. Microbiol. Biotech. (2004) 64:455-464.
3. GUAY DRP: Topical clindamycin in the management of acne vulgaris. Exp. Opin. Pharmacother. (2007) (In Press).
4. CHO SH, IM HT, PARK WS, HA YH, CHOI YW, LEE KT: Simple method for the assay of clindamycin in human plasma by reversed-phase high-performance liquid chromatography with UV detector. Biomed. Chromatogr. (2005) 19:783-787.
5. RECHBERGER GN, FAULER G, WINDISCHHOFER W, KOFELER H, ERWA W, LEIS HJ: Quantitative analysis of dindamycin in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry using d1-N-ethylclindamycin as internal standard. Rapid Commun. Mass Spectrom. (2003) 17:135-139.
6. MARTENS-LOBENHOFFER J, BANDITT P: Sensitive and specific determination of clindamycin in human serum and bone tissue applying liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J. Chromatogr. (2001) 755:143-149.
7. YU LL, CHAO CK, LIAO WJ et al.: Determination of clindamycin in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to the bioequivalence study of clindamycin. J. Chromatogr. (1999) 724:287-294.
8. FIEGER-BUSCHGES H, SCHUSSLER G, LARSIMONT V, BLUME H: Determination of clindamycin in human plasma by high-performance liquid chromatography using coupled columns. J. Chromatogr. (1999) 724:281-286.
9. KASTEN MJ: Clindamycin, metronidazole, and chloramphenicol. Mayo Clin. Proc. (1999) 74:825-833.
10. EPSTEIN ME, AMODIO-GROTON M, SADICK NS: Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J. Am. Acad. Dermatol. (1997) 37:365-381.
11. SMILACK JD, WILSON WR, COCKERILL FR III: Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin. Proc. (1991) 66:1270-1280.
12. SOPER DE: Clindamycin. Obstet. Gynecol. Clin. North Am. (1992) 19:483-496.
13. ZAMBRANO D: Clindamycin in the treatment of obstetric and gynecologic infections: a review. Clin. Ther. (1991) 13:58-80.
14. FALAGAS ME, GORBACH SL: Clindamycin and metronidazole. Med. Clin. North Am. (1995) 79:845-867.
15. FICHERA ME, ROOS DS: A plastid organelle as a drug target in apicomplexan parasites. Nature (1997) 390:407-409.
16. PFEFFERKORN ER, BOROTZ SE: Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Antimicrob. Agents Chemother. (1994) 35:31-37.
17. GOODMAN CD, SU V, MCFADDEN GI: The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. (2007) 152:181-191.
18. SEABERG LS, PARQUETTE AR, GLUZMAN IY, PHILLIPS GW Jr, BRODASKY TF, KROGSTAD DJ: Clindamycin activity against chloroquine-resistant Plasmodium falciparum. J. Infect. Dis. (1984) 150:904-911.
19. PFEFFERKORN ER, NOTHNAGEL RF, BOROTZ SE: Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob. Agents Chemother. (1992) 36:1091-1096.
20. ACHERA ME, BHOPALE MK, ROOS DS: In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. (1995) 39:1530-1537.
21. BECKERS CJM, ROOS DS, DONALD RGK et al.: Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii: implications for the target of macrolide antibiotics. J. Clin. Invest. (1995) 95:367-376.
22. VANVLEM B, VANHOLDER R, DEPAEPE P, VOGELAERS D, RINGOIR S: Immunomodulating effects of antibiotics: literature review. Infection (1996) 24:275-291.
23. ROMANO CC, BENEDETTO N, SABATINI P, GALDIERO E: The effect of clindamycin on human monocytes. J. Chemother. (1989) 1(4 Suppl.):422-424.
24. KAKANO T, HIRAMATSU K, KISHI K, HIRATA N, KADOTA J, NASU M: Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob. Agents Chemother. (2003) 47:363-367.
25. HIRATA N, HIRAMATSU K, KISHI K, YAMASAKI T, ICHIMAYA T, NASU M: Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob. Agents Chemother. (2001) 45:2638-2642.
26. BRINKMANN KC, TALATI AJ, AKBARI RE, MEALS EA, ENGLISH BK: Group B streptococci exposed to rifampin or clindamycin (versus ampicillin or cefotaxime) stimulate reduced production of inflammatory mediators by murine macrophages. Pediatr. Res. (2005) 57:419-423.
27. STEVENS DL, BRYANT AE, HACKETT SP: Antibiotic effects on bacterial viability, toxin producing, and host response. Clin. Infect. Dis. (1995) 20(Suppl. 2):S154-S157.
28. GEMMEL CG, PETERSON PK, SCHMELING D et al.: Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J. Clin. Invest. (1981) 67:1249-1256.
29. SANTS JI, ARBO A, PAVIA N: In vitro and in vivo effects of clindamycin on polymorphonuclear function. Clin. Ther. (1992) 14:578-598.
30. VERINGA EM, VERHOEF J: Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy (1987) 33:243-244.
31. BASSARIS HP, LIANOU PE, SKOUTELIS AT, PAPAVASSILIOU JT: In-vivo effects of clindamycin on polymorphonuclear leucocyte phagocytosis and killing of gram-negative organisms. J. Antimicrob. Chemother. (1987) 19:467-473.
32. CIALDELLA JI, VAVRA JJ, MARSHALL VP: Susceptibility of bacteria to serum lysis or phagocytosis following growth in subinhibitory levels of lincosamide or spectinomycin related antibiotics. J. Antibiot. (1986) 39:978-984.
33. FADEN A, HONG JJ, OGRA PL: In-vivo effects of clindamycin on neutrophil function. J. Antimicrob. Chemother. (1985) 16:649-657.
34. GEMMELL CG, O'DOWD A: Regulation of protein A biosynthesis in Staphylococcus aureus by certain antibiotics: its effect on phagocytosis by leukocytes. J. Antimicrob. Chemother. (1983) 12:587-597.
35. MILATOVIC D, BRAVENY I, VERHOEF J: Clindamycin enhances opsonizarion of Staphylococcus aureus. Anitmicrob. Agents Chemother. (1983) 24:413-417.
36. MILATOVIC D: Effect of subinhibitory antibiotic concentrations on the phagocytosis of Staphylococcus aureus. Eur. J. Clin. Microbiol. (1982) 1:97-101.
37. MAYBERRY-CARSON KJ, TOBER-MEYER B, LAMBE DW Jr, COSTERTON JW: An electron microscopic study of the effect of clindamycin on bacterial adherence and glycocalyx formation in experimental Staphylococcus aureus osteomyelitis. Microbios (1986) 48:189-206.
38. KISHI K, HIRAI K, HIRAMATSU K, YAMASAKI T, NASU M: Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55: B5 and subsequent production of TNF-α and interleukin-1β. Antimicrob. Agents Chemother. (1999) 43:616-622.
39. MATTSON E, VAN DIJK H, VERHOEF J, NORRBY R, ROLLOF J: Supernatants from Staphylococcus epidermidis grown in the presence of different antibiotics induce differential release of TNF-α from human monocytes. Infect. Immunol. (1996) 64:4351-4355.
40. KREMSNER PG: Clindamycin in malaria treatment. J. Antimicrob. Chemother. (1990) 25:9-14.
41. SIVAPALASINGAM S, STIEGBIGEL NH: Macrolides, clindamycin, and ketolides. In: Principles and Practice of Infectious Diseases. Volume 1, 6th Edition. Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York (2005):408-417.
42. FORREST GN, OLDACH DW: Macrolides and clindamycin. In: Infectious Diseases. 3rd Edition. Gorbach SL, Bartlett JG, Blacklow NR (Eds), Lippincott Williams & Wilkins, New York (2004):213-233.
43. DHAWAN VK, THADEPALLI H: Clindamycin: a review of fifteen years of experience. Rev. Infect. Dis. (1982) 4:1133-1153.
44. GEARY TG, JENSEN JB: Effect of antibiotics on Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. (1983) 32:221-225.
45. MCCOLM AA, MCHARDY N: Evaluation of a range of antimicrobial agents against the parasitic protozoa, Plasmodium falciparum, Babesia rodhaini and Theileria parva in vitro. Am. J. Trop. Med. Hyg. (1984) 78:345-354.
46. HASENBEIN ME, WARNER JE, LAMBERT KG, COLE SE, ONDERDONK AB, MCADAM AJ: Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area. J. Clin. Microbiol. (2004) 42:1559-1563.
47. ALOS JI, ARACIL B, OTEO J, GOMEZ-GARCES JL; SPANISH GROUP FOR THE STUDY OF INFECTION IN THE PRIMARY HEALTH CARE SETTING (IAP-SEIMC): Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain. J. Antimicrob. Chemother. (2003) 51:333-337.
48. PETINAKI E, KONTOS F, PRATTI A, SKULAKIS C, MANIATIS AN: Clinical isolates of macrolide-resistant Streptococcus pyogenes in Central Greece. Int. J. Antimicrob. Agents (2003) 21:67-70.
49. ALOS JI, ARACIL B, OTEO J, TORRES C, GOMEZ-GARCES JL; SPANISH GROUP FOR THE STUDY OF INFECTION IN THE PRIMARY HEALTH CARE SETTING: High prevalence of erythromycin-resistant, clindamycin/miocamycin-suceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. J. Antimicrob. Chemother. (2000) 45:605-609.
50. TZELEPI E, KOUPPARI G, MAVROIDI A, ZAPHIROPOULOU A, TZOUVELEKIS LS: Erythromycin resistance amongst group A β-haemolytic streptococci isolated in a paediatric hospital in Athens, Greece. J. Antimicrob. Chemother. (1999) 43:745-746.
51. MARTIN JM, GREEN M, BARBADORA KA, WALD ER: Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N. Engl. J. Med. (2002) 346:1200-1206.
52. TAMAYO J, PEREZ-TRALLERO E, GOMEZ-GARCES JL, ALOS JI; SPANISH GROUP FOR THE STUDY OF INFECTION IN THE PRIMARY HEALTH CARE SETTING: Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J. Antimicrob. Chemother. (2005) 56:780-782.
53. LIN K, TIERNO PM Jr, KOMISAR A: Increasing antibiotic resistance of streptococcus species in New York City. Laryngoscope (2004) 114:1147-1150.
54. CORNAGLIA G, LIGOZZI M, MAZZARIOL A et al. THE ITALIAN SURVEILLANCE GROUP FOR antimicrobial RESISTANCE: Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. The Italian surveillance group for antimicrobial resistance. Clin. Infect. Dis. (1998) 27(Suppl. 1):S87-S92.
55. HEELAN JS, HASENBEIN ME, MCADAM AJ: Resistance of group B streptococcus to selected antibiotics, including erythromycin and clindamycin. J. Clin. Microbiol. (2004) 42:1263-1264.
56. ANDREWS JI, DIEKEMA DJ, HUNTER SK et al.: Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am. J. Obstet. Gynecol. (2000) 183:859-862.
57. GYGAX SE, SCHUYLER JA, KIMMEL LE, TRAMA JP, MORDECHAI E, ADELSON ME: Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob. Agents Chemother. (2006) 50:1875-1877.
58. DE AZAVEDO JC, MCGAVIN M, DUNCAN C, LOW DE, MCGEER A: Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. (2001) 45:3504-3508.
59. PEARLMAN MD, PIERSON CL, FAIX RG: Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet. Gynecol. (1998) 92:258-261.
60. FERNANDEZ M, HICKMAN ME, BAKER CJ: Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob. Agents Chemother. (1998) 42:1517-1519.
61. DIPERSIO LP, DIPERSIO JR: High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B streptococcus. Diagn. Microbiol. Infect. Dis. (2006) 54:79-82.
62. ARACIL B, MINAMBRES M, OTEO J, TORRES C, GOMEZ-GARCES JL, ALOS JI: High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J. Antimicrob. Chemother. (2001) 48:592-594.
63. IOANNIDOU S, TASSIOS PT, KOTSOVILI-TSELENI A, FOUSTOUKOU M, LEGAKIS NJ, VATOPOULOS A: Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int. J. Antimicrob. Agents (2001) 17:195-201.
64. TUOHY M, WASHINGTON JA: antimicrobial susceptibility of viridans group streptococci. Diagn. Microbiol. Infect. Dis. (1997) 29:277-280.
65. JACOBS JA, VAN BAAR GJ, LONDON NH, TJHIE JH, SCHOULS LM, STOBBERINGH EE: Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group. Antimicrob. Agents Chemother. (2001) 45:2375-2377.
66. GROPPO FC, CASTRO FM, PACHECO AB et al.: Antimicrobial resistance of Staphylococcus aureus and oral streptococci strains from high-risk endocarditis patients. Gen. Dent. (2005) 53:410-413.
67. DIAS R, LOURO D, CANICA M: Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period. Antimicrob. Agents Chemother. (2006) 50:2098-2105.
68. SYROGIANNOPOULOS GA, GRIVEA IN, BERATIS NG et al.: Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece. Clin. Infect. Dis. (1997) 25:188-194.
69. BONOFIGLIO L, OJEDA MI, DE MIER C et al.: Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital. Int. J. Antimicrob. Agents (2005) 25:260-263.
70. DIPERSIO LP, DIPERSIO JR, BEACH JA, DEFINE LA: Rise of Streptococcus pneumoniae isolates containing both erm(B) and mef(E) genes from an adult tertiary care community hospital system. Diagn. Microbiol. Infect. Dis. (2006) 55:327-331.
71. SCHRECKENBERGER PC, ILENDO E, RISTOW KL: Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus. and coagulase-negative staphylococci in a community and a tertiary care hospital. J. Clin. Microbiol. (2004) 42:2777-2779.
72. SIBERRY GK, TEKLE T, CARROLL K, DICK J: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin. Infect. Dis. (2003) 37:1257-1260.
73. CHAVEZ-BUENO S, BOZDOGAN B, KATZ K et al.: Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob. Agents. Chemother. (2005) 49:2283-2288.
74. LEVIN TP, SUH B, AXELROD P, TRUANT AL, FEKETE T: Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrob. Agents Chemother. (2005) 49:1222-1224.
75. BAIOCCHI P, GALIE M, SANTINI C et al.: In vitro susceptibility of Staphylococcus aureus isolated from blood to currently used antistaphylococcal drugs. J. Chemother. (1998) 10:25-28.
76. FRANK AL, MARCINAK JF, MANGAT PD, SCHRECKENBERGER PC: Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr. Infect. Dis. J. (1999) 18:993-1000.
77. MUNCKHOF WJ, HARPER J, SCHOONEVELDT J, NIMMO GR: Recent appearance of clindamycin resistance in community-acquired methicillin-resistant Staphylococcus aureus (MRSA) in south-east Queensland. Med. J. Aust. (2002) 176:243-244 (Letter).
78. FRANK AL, MARCINAK JF, MANGAT PD et al.: Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. (2002) 21:530-534.
79. HUANG H, FLYNN NM, KING JH, MONCHAUD C, MORITA M, COHEN SH: Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J. Clin. Microbiol. (2006) 44:2423-2427.
80. PATEL M, WAITES KB, MOSER SA, CLOUD GA, HOESLEY CJ: Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J. Clin. Microbiol. (2006) 44:2481-2484.
81. MUNCKHOF WJ, KLEINSCHMIDT SL, SCHOONEVELDT JM: Inducible clindamycin resistance in erythromycin-resistant, non-multiresistant, methicillin-resistant Staphylococcus aureus. Pathology. (2004) 36:373-374.
82. CRUM NF, LEE RU, THORNTON SA et al.: Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am. J. Med. (2006) 119:943-951.
83. ARCIOLA CR, CAMPOCCIA D, GAMBERINI S et al.: Antibiotic resistance in exopolysaccharide-forming Staphylococcus epidermidis clinical isolates from orthopedic implant infections. Biomaterials (2005) 26:6530-6535.
84. LABBE AC, BOURGAULT AM, VINCELETTE J, TURGEON PL, LAMOTHE F: Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob. Agents Chemother. (1999) 43:2517-2519.
85. OTEO J, ARACIL B, ALOS JI, GOMEZ-GARCES JL: High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. J. Antimicrob. Chemother. (2000) 45:691-693.
86. LEE K, CHONG Y, JEONG SH, XU XS, KWON OH: Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea. Clin. Infect. Dis. (1996) 23(Suppl. 1):S73-S77.
87. ALDRIDGE KE, ASHCRAFT D, CAMBRE K, PIERSON CL, JENKINS SG, ROSENBLATT JE: Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents. Chemother. (2001) 45:1238-1243.
88. SNYDMAN DR, JACOBUS NV, MCDERMOTT IA et al.: National survery on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997 - 2000. Clin. Infect. Dis. (2002) 35(Suppl. 1):S126-S134.
89. TENG LJ, HSUEH PR, TSAI JC, LIAW SJ, HO SW, LUH KT: High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob. Agents. Chemother. (2002) 46:2908-2913.
90. PAPAPARASKEVAS J, PANTAZATOU A, KATSANDRI A et al.: Multicentre survey of the in vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated gram-negative anaerobic bacteria in Greece. Clin. Microbiol. Infect. (2005) 11:820-824.
91. FILLE M, MANGO M, LECHNER M, SCHAUMANN R: Bacteroides fragilis group: trends in resistance. Curr. Microbiol. (2006) 52:153-157.
92. SNYDMAN DR, JACOBUS NV, MCDERMOTT LA et al.: National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob. Agents. Chemother. (2007) 51:1649-1655.
93. LIN WJ, LO WT, CHU CC, CHU ML, WANG CC: Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infections in children. J. Microbiol. Immunol. Infect. (2006) 39:249-254.
94. KHEMALEELAKUL S, BAUMGARTNER JC, PRUKSA-KORN S: Identification of bacteria in acute endodontic infections and their antimicrobial susceptibility. Oral Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. (2002) 94:746-755.
95. BROOK I, LEWIS MAO, SANDOR GKB, JEFFCOAT M, SAMARANAYAKE LP, ROJAS JV: Clindamycin in dentistry: more than just effective prophylaxis in dentistry? Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. (2005) 100:550-558.
96. KURIYAMA T, KARASAWA T, NAKAGAMA K, SAIKI Y, YAMAMOTO E, NAKAMURA S: Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. (2000) 90:600-608.
97. ALDRIDGE KE, ASHCRAFT D, CAMBRE K, PIERSON CL, JENKINS SG, ROSENBLATT JE: Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. (2001) 45:1238-1243.
98. TOMAS I, ALVAREZ M, LIMERES J, DIZ P: Clindamycin in dentistry: is it an effective prophylaxis for endocarditis? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2006) 101:698-700.
99. OLLIARO P: Mode of action and mechanism of resistance for antimalarial drugs. Pharmacol. Ther. (2001) 89:207-219.
100. PANAGEA S, PERRY JD, GOULD FK: Should clindamycin be used as a treatment of patients with infections caused by erythromycin-resistant staphylococci? J. Antimicrob. Chemother. (1999) 44:581-582.
101. RANEY PM, TENOVER FC, CAREY RB, MCGOWAN JE Jr, PATEL JB: Investigation of inducible clindamycin and telithromycin resistance in isolates of β-hemolytic streptococci. Diagn. Microbiol. Infect. Dis. (2006) 55:213-218.
102. STEWARD CD, RANEY PM, MORRELL AK et al.: Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J. Clin. Microbiol. (2005) 43:1716-1721.
103. FIEBELKORN KR, CRAWFORD SA, MCELMEEL ML, JORGENSEN JH: Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J. Clin. Microbiol. (2003) 41:4740-4744.
104. BORIN MT, RYAN KK, HOPKINS NK: Systemic absorption of clindamycin after intravaginal administration of clindamycin phosphate ovule or cream. J. Clin. Pharmacol. (1999) 39:805-810.
105. GATTI G, MALENA M, CASAZZA R, BORIN M, BASSETTI M, CRUCIANI M: Penetration of clindamycin and its metabolite N-demethylclindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS. Antimicrob. Agents Chemother. (1998) 42:3014-3017.
106. TOMA MB, SMITH KM, MARTIN CA, RAPP RP: Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Orthopedics (2006) 29:497-501.
107. WYNALDA MA, HUTZLER JM, KOETS MD, PODOLL T, WIENKERS LC: In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab. Dispos. (2003) 31:878-887.
108. RICE HE, BROWN RL, GOLLIN G et al.: Results of a pilot trial comparing prolonged intravenous antibiotics with sequential intravenous/ oral antibiotics for children with perforated appendicitis. Arch. Surg. (2001) 136:1391-1395.
109. COLLINS MD, DAJANI AS, KIM KS et al.: Comparison of ampicillin/ sulbactam plus aminoglycoside vs. ampicillin plus clindamycin plus aminoglycoside in the treatment of intraabdominal infections in children. Pediatr. Infect. Dis. J. (1998) 17(Suppl. 3):S15-S18.
110. MAHAKIT P, VINCENTE JG, BUTT DI, ANGELI G, BANSAL S, ZAMBRANO D: Oral clindamycin 300 mg bid compared with oral amoxicillin/clavulanic acid 1 g bid in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group A β-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years. Clin. Ther. (2006) 28:99-109.
111. ORRLING A, STJERNQUIST-DESATNIK A, SCHALEN C: Clindamycin in recurrent group A streptococcal pharyngotonsillitis - an alternative to tonsillectomy? Acta Oto-Laryngol. (1997) 117:618-622.
112. JACOBSON SJ, GRIFFITHS K, DIAMOND S et al.: A randomized controlled trial of penicillin vs clindamycin for the treatment of aspirarion pneumonia in children. Arch. Pediatr. Adolesc. Med. (1997) 151:701-704.
113. KADOWAKI M, DEMURA Y, MIZUNO S et al.: Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest (2005) 127:1276-1282.
114. FARO S, SKOKOS CK; CLINDESSE INVESTIGATORS GROUP: The efficacy and safety of a single dose of Clindesse™ vaginal cream versus a seven-dose regimen of Cleocin® vaginal cream in patients with bacterial vaginosis. Infect. Dis. Obstet. Gynecol. (2005) 13:155-160.
115. LIVINGSTON JC, LLATA E, RINEHART E et al.: Gentamicin and clindamycin therapy in postpartum endometritis: the efficacy of daily dosing versus dosing every 8 hours. Am. J. Obstet. Gynecol. (2003) 188:149-152.
116. DIAMANTOPOULOS EJ, HARITOS D, YFANDI G et al.: Management and outcome of severe diabetic foot infections. Exp. Clin. Endocrinol Diab. (1998) 106:346-352.
117. LAZZARINI L, BRUNELLO M, PADULA E, DE LALLA F: Prophylaxis with cefazolin plus clindamycin in clean-contaminated maxillofacial surgery. J. Oral Maxillofac. Surg. (2004) 62:567-570.
118. RODRIGO JP, ALVAREZ JC, GOMEZ JR, SUAREZ C, FERNANDEZ JA, MARTINEZ JA: Comparison of three prophylactic antibiotic regimens in clean-contaminated head and neck surgery. Head Neck (1997) 19:188-193.
119. PUKRITTAYAKAMEE S, CLEMENS R, CHANTRA A et al.: Therapeutic responses to antibacterial drugs in vivax malaria. Trans. Roy. Soc. Trop. Med. Hyg. (2001) 95:524-528.
120. RAMHARTER M, OYAKHIROME S, KLOUWENBERG PK et al.: Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin. Infect. Dis. (2005) 40:1777-1784.
121. BORRMANN S, LUNDGREN I, OYAKHIROME S et al.: Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob. Agents Chemother. (2006) 50:2713-2718.
122. MCGREADY R, CHO T, SAMUEL VILLEGAS L et al.: Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans. Roy. Soc. Trop. Med. Hyg. (2001) 95:651-656.
123. BORRMANN S, ISSIFOU S, ESSER G et al.: Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J. Infect. Dis. (2004) 190:1534-1540.
124. BORRMANN S, ADEGNIKA AA, MATSIEGUI PB et al.: Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children. J. Infect. Dis. (2004) 189:901-908.
125. OYAKHIROME S, ISSIFOU S, PONGRATZ P et al.: Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob. Agents Chemother. (2007) 51:1869-1871.
126. TOMA E, THORNE A, SINGER J et al.; CTN PCP STUDY GROUP: Clindamycin with primaquine vs. trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). Clin. Infect. Dis. (1998) 27:524-530.
127. ZIMBELMAN J, PALMER A, TODD J: Improved outcome of clindamycin compared with β-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr. Infect. Dis. J. (1999) 18:1096-1100.
128. MARTINEZ-AGUILAR G, HAMMERMAN WA, MASON EO Jr, KAPLAN SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr. Infect. Dis. J. (2003) 22:593-598.
129. WYNN M, DALOVISIO JR, TICE AD, JIANG X: Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South. Med. J. (2005) 98:590-595.
130. SOLOMKIN JS, MAZUSKI JE, BARON EJ et al.: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. (2003) 37:997-1005.
131. KLEIN NC, CUNHA BA: New uses of older antibiotics. Med. Clin. North Am. (2001) 85:125-132.
132. GUDIOL F, MANRESA F, PALLARES R et al.: Clindamycin vs. penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch. Intern. Med. (1990) 150:2525-2529.
133. PERLINO CA: Metronidazole vs. clindamycin treatment of anerobic pulmonary infection failure of metronidazole therapy. Arch. Intern. Med. (1981) 141:1424-1427.
134. LEVISON ME, MANGURA CT, LORBER B et al.: Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann. Intern. Med. (1983) 98:466-471.
135. MANDELL LA, WUNDERINK RG, ANZUETO A et al.: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. (2007) 44(Suppl. 2):S27-S72.
136. ANONYMOUS: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171:388-416.
137. KOENIG SM, TRUWIT JD: Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin. Microbiol. Rev. (2006) 19:637-657.
138. TUNKEL AR, HARTMAN BJ, KAPLAN SL et al.: Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. (2004) 39:1267-1284.
139. LU C-H, CHANG W-N, LIU C-C: Strategies for the management of bacterial brain abscess. J. Clin. Neurosci. (2006) 13:979-985.
140. BRADLEY JS, SCHELD WM: The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin. Infect. Dis. (1997) 24(Suppl. 2):S213-S221.
141. MILLER JM, MARTIN DH: Treatment of Chlamydia trachomatis infections in pregnant women. Drugs (2000) 60:597-605.
142. ANONYMOUS: National guideline for the management of pelvic infection and perihepatitis. Clinical effectiveness group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm. Infect. (1999) 75(Suppl. 1):S54-S56.
143. DUFF P: Antibiotic selection in obstetrics: making cost-effective choices. Clin. Obstet. Gynecol. (2002) 45:59-72.
144. KOUMANS EH, MARKOWITZ LE, HOGAN V, CDC BV WORKING GROUP: Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin. Infect. Dis. (2002) 35(Suppl. 2):S152-S172.
145. ANONYMOUS: National guideline for the management of bacterial vaginosis. Clinical effectiveness group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm. Infect. (1999) 75(Suppl. 1):S16-S18.
146. STEVENS DL, BISNO AL, CHAMBERS HF et al.: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. (2005) 41:1373-1406.
147. LIPSKY BA, BERENDT AR, DEERY HG et al.: Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. (2004) 39:885-910.
148. RUSSELL NE, PACHOREK RE: Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes. Ann. Pharmacother. (2000) 34:936-939.
149. NORRBY SR, NORRBY-TEGLUND A: Infections due to group A streptococcus: new concepts and potential treatment strategies. Ann. Acad. Med. Singapore (1997) 26:691-693.
150. DAVIES HD, SCHWARTZ B: Invasive group A streptococcal infections in children. Adv. Pediatr. Infect. Dis. (1999) 14:129-145.
151. PILLAI A, THOMAS S, WILLIAMS C: Clindamycin in the treatment of group G β-haemolytic streptococcal infections. J. Infect. (2005) 51:E207-E211.
152. PUSPONEGORO EH, WIRYADI BE: Clindamcyin and cloxacillin compared in the treatment of skin and soft-tissue infections. Clin. Ther. (1990) 12:236-241.
153. MENDONCA CO, GRIFFITHS CE: Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br. J. Dermatol. (2006) 154:977-978.
154. PELTOLA H, UNKILA-KALLIO L, KALLIO MJ: Simplified treatment of acute staphylococcal osteomyelitis in children. The Finnish study group. Pediatrics (1997) 99:846-850.
155. KAPLAN SL, MASON EO Jr, FEIGIN RD: Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children. South. Med. J. (1982) 75:138-142.
156. RODRIGUEZ W, ROSS S, KHAN W, MCKAY D, MOSKOWITZ P: Clindamycin in the treatment of osteomyelitis in children: a report of 29 cases. Am. J. Dis. Child. (1977) 131:1088-1093.
157. FEIGIN RD, PICKERING LK, ANDERSON D, KEENEY RE, SHACKLEFORD PG: Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics (1975) 55:213-223.
158. MARTINEZ-AGUILAR G, HAMMERMAN WA, MASON ED Jr, KAPLAN SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr. Infect. Dis. J. (2003) 22:593-598.
159. ARNOLD SR, ELIAS D, BUCKINGHAM SC et al.: Changing patterns of acute hematogenous osteomyelitis and septic arthritis. Emergence of community-associated methicillin-resistant Staphylococcus aureus. J. Pediatr. Orthop. (2006) 26:703-708.
160. KAPLAN SL: Treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr. Infect. Dis. J. (2005) 24:457-458.
161. BARNES EV II, DOOLEY DP, HEPBURN MJ, BAUM SE: Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus soft tissue infections treated with antibiotics other than vancomycin. Milit. Med. (2006) 171:504-507.
162. LEW1S JS II, JORGENSEN JH: Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. (2005) 40:280-285.
163. WALSH SR, FERRARO MJ, DURAND ML: Clindamycin-resistant Streptococcus pyogene: report of a case. Diagn. Microbiol. Infect. Dis. (2004) 49:223-225.
164. SWIFT JQ, GULDEN WS: Antibiotic therapy - managing odontogenic infections. Dent. Clin. North Am. (2002) 46:623-633.
165. SANDOR GK, LOW DE, JUDD PL, DAVIDSON RJ: Antimicrobial treatment options in the management of odontogenic infections. J. Can. Dent. Assoc. (1998) 64:508-514.
166. ADDY LD, MARTIN MV: Clindamycin and dentistry. Br. Dent. J. (2005) 199:23-26.
167. MORRIS-JONES SD, EASTERBROOK PJ: Current issues in the treatment and prophylaxis of Pneumocystis carinii pneumonia in HIV infection. J. Antimicrob. Chemother. (1997) 40:315-318.
168. THOMAS CF Jr, LIMPER AH: Pneumocystis pneumonia. N. Engl. J. Med. (2004) 350:2487-2498.
169. NEVILLE K, RENBARGER J, DREYER Z: Pneumonia in the immunocompromised pediatric cancer patient. Semin. Resp. Infect. (2002) 17:21-32.
170. VILAR FJ, KHOO SH, WALLEY T: The management of Pneumocystis carinii pneumonia. Br. J. Clin. Pharmacol. (1999) 47:605-609.
171. SMEGO RA Jr, NAGAR S, MALOBA B, POPARA M: A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch. Intern. Med. (2001) 161:1529-1533.
172. FILBIN MR, MYLONAKIS EE, CALLEGARI L, LEGOME E: Babesiosis. J. Emerg. Med. (2001) 20:21-24.
173. CORPELET C, VACHER P, COUDORE F, LAURICHESSE H, CONORT N, SOUWEINE B: Role of quinine in life-threatening Babesia divergens infection successfully treated with clindamycin. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:74-75.
174. GRIFFITH KS, LEWIS LS, MALI S, PARISE ME: Treatment of malaria in the United States. A systematic review. JAMA (2007) 297:2264-2277.
175. LELL B, KREMSNER PG: Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. (2002) 46:2315-2320.
176. RAMHARTER M, NOEDL H, WINKLER H et al.: In vitro activity and interaction of clindamycin combined with dihydroartemisinin against Plasmodium falciparum. Antimicrob. Agents Chemother. (2003) 47:3494-3499.
177. WIESNER J, HENSCHKER D, HUTCHINSON DB, BECK E, JOMAA H: In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. (2002) 46:2889-2894.
178. BEHBAHANI R, MOSHFEGHI M, BAXTER JD: Therapeutic approaches for AIDS-related toxoplasmosis. Ann. Pharmacother. (1995) 29:760-768.
179. IANNUCCI AA, HART LL: Clindamycin in the treatment of toxoplasmosis in AIDS. Ann. Pharmacother. (1992) 26:645-647.
180. 60Co-γ-photon-irradiated and sham-irradiated mice. J. Antimicrob. Chemother. (2005) 56:1074-1080.
181. KLEMPNER MS, STYRT B: Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA (1998) 260:2682-2685.
182. BRATZLER DW, HOUCK PM; SURGICAL INFECTION PREVENTION GUIDELINE WRITER'S WORKGROUP: antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am. J. Surg. (2005) 189:395-404.
183. HIROTA WK, WORTMANN GW, MAYDONOVITCH CL et al.: The effect of oral decontamination with clindamycin palmitate on the incidence of bacteremia after esophageal dilation: a prospective trial. Gatstrointest. Endo. (1999) 50:475-479.
184. ROBERTS GJ, WATTS R, LONGHURST P, GARDNER P: Bacteremia of dental origin and antimicrobial sensitivity following oral surgical procedures in children. Pediatr. Dent. (1998) 20:28-36.
185. DIZ DIOS P, TOMAS CARMONA I, LIMERES POSSE J et al.: Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions. Antimicrob. Agents Chemother. (2006) 50:2996-3002.
186. WILSON W, TAUBERT KA, GEWITZ M et al.: Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation (2007) DOI: 10.1161/CIRCULATIONAHA.106.183095.
187. LOO VG, POIRIER L, MILLER MA et al.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. (2005) 353:2442-2449.
188. MUTO CA, POKRYWKA M, SHUTT K et al.: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. (2005) 26:273-280.
189. MCDONALD LC: Clostridium difficile: responding to a new threat from an old enemy. Infect. Control Hosp. Epidemiol. (2005) 26:672-675.
190. BORRIELLO SP, DAVIES HA, KAMIYA S et al.: Virulence factors of Clostridium difficile. Rev. Infect. Dis. (1990) 12(Suppl. 2):S185-S191.
191. BARTH A, AKTORIES K, POPOFF MR et al.: Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev. (2004) 68:373-402.
192. BARTLETT JG: Antibiotic-associated diarrhea. N. Engl. J. Med. (2002) 346:334-339.
193. BOUZA E, BURILLO A, MUNOZ P: Antimicrobial therapy of Clostridium difficile-associated disease. Med. Clin. North Am. (2006) 90:1141-1163.
194. VIKENES K, LUND-TONNESEN S, SCHREINER A: Clostridium difficile-associated diarrhea after short-term vaginal administration of clindamycin. Am. J. Gastroenterol. (1999) 94:1969-1970.
195. MEADOWCRAFT AM, DIAZ PR, LATHAM GS: Clostndium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. Ann. Pharmacother. (1998) 32:309-311.
196. TREXLER MF, FRASER TG, JONES MP: Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream. Am. J. Gastroenterol. (1997) 92:2112-2113.
197. PARRY MF, RHA CK: Pseudomembranous colitis caused by topical clindamycin phosphate. Arch. Dermatol. (1986) 122:583-584.
198. MILSTONE EB, MCDONALD AJ, SCHOLHAMER CF Jr: Pseudomembranous colitis after topical application of clindamycin. Arch. Dermatol. (1981) 117:154-155.
199. GEORGE WL: Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects. Rev. Infect. Dis. (1984) 6(Suppl. 1):S208-S213.
200. TEDESCO FJ, BARTON RW, ALPERS DH: Clindamycin-associated colitis: a prospective study. Ann. Intern. Med. (1974) 81:429-433.
201. BARTLETT JG, TAYLOR NS, CHANG TW, DZINK JA: Clinical and laboratory observations of Clostridium difficile colitis. Am. J. Clin. Nut. (1980) 33:2521-2526.
202. THAMLIKITKUL V, DANPAKDI K, CHOKLOIKAEW S: Incidence of diarrhea and Clostridium difficile toxin in stools from hospitalized patients receiving clindamycin, β-lactams, or nonantibiotic medications. J. Clin. Gastroenterol. (1996) 22:161-163.
203. ZIMMERMAN RK: Risk factors for Clostridium difficile cytotoxin-positive diarrhea after control for horizontal transmission. Infect. Control Hosp. Epidemiol. (1991) 12:96-100.
204. NELSON DE, AUERBACH SB, BALTCH AL et al.: Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect. Control Hosp. Epidemiol. (1994) 15:88-94.
205. ANAND A, BASHEY B, MIR T, GLATT AE: Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am. J. Gastroenterol. (1994) 89:519-523.
206. GAYNES R, RIMLAND D, KILLUM E et al.: Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis. (2004) 38:640-645.
207. GERDING DN: Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin. Infect. Dis. (2004) 38:646-648.
208. AL AHDAL O, BEVAN DR: Clindamycin-induced neuromuscular blockade. Can. J. Anaesth. (1995) 42:614-617.
209. BEST JA, MARASHI AH, POLLAN LD: Neuromuscular blockade after clindamycin administration: a case report. J. Oral. Maxillofac. Surg. (1999) 57:600-603.
210. FOGDALL RP, MILLER RD: Prolongation of a pancuronium-induced neuromuscular blockade by clindamycin. Anesthesiology (1974) 41:407-409.
211. JEDEIKIN R, DOLGUNSKI E, KAPLAN R, HOFFMAN S: Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. Anaesthesia (1987) 42:858-860.
212. SLOAN PA, RASUL M: Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. Anest. Analg. (2002) 94:123-124.
213. SCHULZE J, TOEPFER M, SCHROFF KC et al.: Clindamycin and nicotinic neuromuscular transmission. Lancet (1999) 354:1792-1793.
214. CZEIZEL AE, ROCKENBAUER M, SORENSEN HT, OLSEN J: A teratological study of lincosamides. Scand. J. Infect. Dis. (2000) 32:579-580.
215. THURNHEER R, LAUBE I, SPEICH R: Possible interaction between clindamycin and cyclosporin. BMJ (1999) 319:163.
216. FRUSCIO R, LISSONI AA, FRAPOLLI R et al.: Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemother. Pharmacol. (2006) 58:319-325.
217. FISCELLA R, PEYMAN GA, FISHMAN PH: Duration of therapeutic levels of intravitreally injected liposome-encapsulated clindamycin in the rabbit. Can. J. Ophthalmol. (1987) 22:307-309.
218. LEWIS C: Clinically useful antibiotics obtained by directed chemical modification-lincomycins. Fed. Proc. (1974) 33:2303-2306.
219. BIRKENMEYER RD, KROLL SJ, LEWIS C, STERN KF, ZURENKO GE: Synthesis and antimicrobial activity of clindamycin analogues: pirlimycin, 1,2, a potent antibacterial agent. J. Med. Chem. (1984) 27:216-223.
220. DHAWAN VK, BANSAL MB, THADEPALLI H: In vitro activity of pipecolic acid amide of clindamycin (U-57930E) on anaerobic bacteria compared with those of clindamycin, cefoxitin, and chloramphenicol. Antimicrob. Agents Chemother. (1982) 22:350-351.
221. QADRI SM, KARIM MR, FLOURNOY DJ: In vitro activity of U-57930E against anaerobic bacteria and its comparison with clindamycin, ampicillin, carbenicillin and tetracycline. J. Antibiot. (1983) 36:42-46.
222. GARCIA-RODRIGUEZ JA, GARCIA-SANCHEZ JE, PRIETO J, SANCHEZ DE S LORENZO A: Activity of pirlimycin (U57930E) against strains of the Bacteroides fragilis group. Antimicrob. Agents Chemother. (1982) 22:893-894.
223. WESTBLOM TU, MIDKIFF BR, CZINN SJ: In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A). Eur. J. Clin. Microbiol. Infect. Dis. (1993) 12:560-562.
224. EVANS ME, PATTERSON LS, STRATTON CW: In vitro comparison of clindamycin and pirlimycin (U-57930E) activity against Staphylococcus aureus. Antimicrob. Agents Chemother. (1982) 22:334-335.
225. AHONKHAI VI, CHERUBIN CE, SHULMAN MA, JHAGROO M, BANCROFT U: In vitro activity of U-57930E, a new clindamycin analog, against aerobic gram-positive bacteria. Antimicrob. Agents Chemother. (1982) 21:902-905.
226. YANCEY RJ Jr, KINNEY ML, FORD CW: Efficacy of lincosaminide antibiotics in the treatment of experimental staphylococcal mastitis in lactating mice. J. Antimicrob. Chemother. (1985) 15:219-232.
227. SHAH JA, WEBER DJ: High-performance liquid chromatographic assay of pirlimycin in human serum and urine using 9-fluorenylmethylchloroformate. J. Chromatogr. (1984) 309:95-105.
228. HELLER DN: Determination of pirlimycin residue in milk by liquid chromatographic analysis of the 9-fluorenylmethyl chloroformate derivative. J. AOAC Int. (1997) 80:975-981.
229. HELLER DN: Determination and confirmation of pirlimycin residue in bovine milk and liver by liquid chromatography/thermospray mass spectrometry: interlaboratory study. J. AOAC Int. (1996) 79:1054-1061.
230. HORNISH RE, CAZERS AR, CHESTER ST Jr, ROOF RD: Identification and deterioration of pirlimycin residue in bovine milk and liver by high-performance liquid chromatography-thermospray mass spectrometry. J. Chromatogr. Biomed. App. (1995) 674:219-235.
231. LUTHJE P, SCHWARZ S: Molecular analysis of constitutively expressed erm(C) genes selected in vitro in the presence of the non-inducers pirlimycin, spiramycin and tylosin. J. Antimicrob. Chemother. (2007) 59:97-101.
232. LOCH IM, GLENN K, ZADOKS RN: Macrolide and lincosamide resistance genes of environmental streptococci from bovine milk. Vet. Microbiol. (2005) 111:133-138.
233. LUTHJE P, SCHWARZ S: Antimicrobial resistance of coagulase-negative staphylococci from bovine subclinical mastitis with particular reference to macrolide-lincosamide resistance phenotypes and genotypes. J. Antimicrob. Chemother. (2006) 57:966-969.
234. GENTILINI E, DENAMIEL G, BETANCOR A, REBUELTO M, RODRIGUEZ FERMEPIN M, DE TORREST PA: Antimicrobial susceptibility of coagulase-negative staphylococci isolated from bovine mastitis in Argentina. J. Dairy Sci. (2002) 85:1913-1917.
235. MAKOVEC JA, RUEGG PL: Antimicrobial resistance of bacteria isolated from dairy cow milk samples submitted for bacterial culture: 8,905 samples (1994 - 2001). J. Am. Vet. Med. Assoc. (2003) 222:1582-1589.
236. THORNSBERRY C, MARLER JK, WATTS JL, YANCEY RJ Jr: Activity of pirlimycin against pathogens from cows with mastitis and recommendations for disk diffusion tests. Antimicrob. Agents Chemother. (1993) 37:1122-1126.
237. SALMON SA, WATTS JL, AARESTRUP FM, PANKEY JW, YANCEY RJ Jr: Minimum inhibitory concentrations for selected antimicrobial agents against organisms isolated from the mammary glands of dairy heifers in New Zealand and Denmark. J. Dairy Sci. (1998) 81:570-578.
238. WATTS JL, SALMON SA, YANCEY RJ Jr et al.: Antimicrobial susceptibility of microorganisms isolated from the mammary glands of dairy heifers. J. Dairy Sci. (1995) 78:1637-1648.
239. GENTILINI E, DENAMIEL G, LLORENTE P, GODALY S, REBUELTO M, DEGREGORIO O: Antimicrobial susceptibility of Staphylococcus aureus isolated from bovine mastitis in Argentina. J. Dairy Sci. (2000) 83:1224-1227.
240. DEOLIVEIPA AP, WATTS JL, SALMON SA, AARESTRUP FM: Antimicrobial susceptibility of Staphylococcus aureus isolated from bovine mastitis in Europe and the United States. J. Dairy. Sci. (2000) 83:855-862.
241. BEZEK DM: Genus identification and antibiotic susceptibility patterns of bacterial isolates from cows with acute mastitis in a practice population. J. Am. Vet. Med. Assoc. (1998) 212:404-406.
242. ERSKINE RJ, WALKER RD, BOLIN CA, BARTLETT PC, WHITE DG: Trends in antibacterial susceptibility of mastitis pathogens during a seven-year period. J. Dairy Sci. (2002) 85:1111-1118.
243. ROSSITTO PV, RUIZ L, KIKUCHI Y et al.: Antibiotic susceptibility patterns for environmental streptococci isolated from bovine mastitis in central California dairies. J. Dairy Sci. (2002) 85:132-138.